Tieteelliset julkaisut

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. (Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pan.., 2017)
Julkaisu:Scientific Reports
Tiivistelmä: Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (TRD).

Quality pre and post treatment fMRI data were collected from 16 of 19 patients. Decreased depressive symptoms were observed in all 19 patients at 1-week post-treatment and 47% met criteria for response at 5 weeks. Whole-brain analyses revealed post-treatment decreases in CBF in the temporal cortex, including the amygdala. Decreased amygdala CBF correlated with reduced depressive symptoms. Focusing on a priori selected circuitry for RSFC analyses, increased RSFC was observed within the default-mode network (DMN) post-treatment. Increased ventromedial prefrontal cortex-bilateral inferior lateral parietal cortex RSFC was predictive of treatment response at 5-weeks, as was decreased parahippocampal-prefrontal cortex RSFC.

These data fill an important knowledge gap regarding the post-treatment brain effects of psilocybin, and are the first in depressed patients. The post-treatment brain changes are different to previously observed acute effects of psilocybin and other 'psychedelics' yet were related to clinical outcomes. A 'reset' therapeutic mechanism is proposed.
Yhdiste:Psilosybiini
Aihe:Yleiset vaikutukset, aivotutkimus
Menetelmät:fMRI
Otoskoko:16
Muuta:
Tagit:
DOI:10.1038/s41598-017-13282-7
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640601/
LinkkiPysyvä linkki julkaisun sivulle tietokannassamme